{
    "clinical_study": {
        "@rank": "126177", 
        "arm_group": [
            {
                "arm_group_label": "Experimental: EVP-6308; Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "low dose, Capsule, Twice Daily, Day 1 through Day 14"
            }, 
            {
                "arm_group_label": "Experimental: EVP-6308; Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "intermediate dose, Capsule, Once Daily, Day 1 through Day 14"
            }, 
            {
                "arm_group_label": "Experimental: EVP-6308; Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "high dose, Capsule, Once Daily, Day 1 through Day 14"
            }, 
            {
                "arm_group_label": "Placebo Comparator; Arm 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, Capsule, Once Daily, Day 1 through Day 14"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral\n      dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308\n      administered for 14 days in subjects with schizophrenia who are on a stable anti-psychotic\n      regimen."
        }, 
        "brief_title": "Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics", 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        \u2022 Diagnosed with schizophrenia, male or female subjects, 18 to 60 years of age\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities on physical examination, medical history,  ECG,\n             vital signs, laboratory values, or unstable medical or psychiatric illness\n\n          -  Any disorder that may interfere with drug absorption\n\n          -  Clinically significant allergy or sensitivity to medications Positive test for human\n             immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C\n             antibody\n\n          -  Pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037074", 
            "org_study_id": "EVP-6308-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Experimental: EVP-6308; Arm 1", 
                    "Experimental: EVP-6308; Arm 2", 
                    "Experimental: EVP-6308; Arm 3"
                ], 
                "description": "Arms 1, 2, 3", 
                "intervention_name": "Drug: EVP-6308", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Comparator; Arm 4", 
                "description": "Arm 4", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antipsychotic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Phosphodiesterase 10 inhibitor", 
        "lastchanged_date": "April 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Long Beach", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen", 
        "overall_contact": {
            "email": "nbuerstatte@forumpharma.com", 
            "last_name": "Nathan Buerstatte", 
            "phone": "617-374-5784"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vital signs measurements, Clinical laboratory tests, Physical examination, ECG findings, Columbia-Suicide Severity Rating Scale.  Adverse events and concomitant medications will be collected from the time of signing the informed consent.", 
            "measure": "Safety and tolerability of EVP-6308 in subjects with schizophrenia currently receiving stable treatment with up to 2 atypical antipsychotics", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Day 21 or Early Termination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK parameters to be determined for EVP-6308 and EVP-6308 N-oxide metabolite include Cmax, Tmax,, AUC, and t1/2.  PK parameters to be determined for the antipsychotic include Cmax, Tmax, AUC, and CL/F.", 
                "measure": "Pharmacokinetics of EVP-6308 in subjects with schizophrenia and the potential for EVP-6308 to affect the pharmacokinetic properties of the antipsychotic regimen", 
                "safety_issue": "No", 
                "time_frame": "Day -1 through Day 16"
            }, 
            {
                "description": "Quantitative EEG, Positive and Negative Syndrome Scale, Clinician Global Impression - Severity, Barnes Akathisia Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, Cognitive Battery.", 
                "measure": "Potential pharmacodynamics effects of EVP-6308", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 21 or Early Termination"
            }
        ], 
        "source": "FORUM Pharmaceuticals Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "FORUM Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}